Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1243205rdf:typepubmed:Citationlld:pubmed
pubmed-article:1243205lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1243205lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1243205lifeskim:mentionsumls-concept:C0205470lld:lifeskim
pubmed-article:1243205lifeskim:mentionsumls-concept:C0069774lld:lifeskim
pubmed-article:1243205pubmed:issue5lld:pubmed
pubmed-article:1243205pubmed:dateCreated1976-3-30lld:pubmed
pubmed-article:1243205pubmed:abstractTextImmunological function was evaluated in 9 patients who received oxisuran at a dose range of 5-90 mg/kg, for periods of 5-40 weeks. Bone marrow cytotoxicity and lymphopenia did not occur. Established humoral immunological reactions were unaffected by oxisuran. Only 6 of 19 previously positive skin tests reverted to negative. Primary cellular immune reactivity was markedly suppressed. Allogenic skin graft survival was prolonged to a mean of 30.7 days and only 2 of 9 patients were successfully sensitized to dinitrochlorobenzene and Keyhole limpet hemocyanin, respectively. Both IgG and IgM responses to primary typhoid immunization were inhibited. In vitro peripheral blood lymphocyte activity in phytohemagglutinin and mixed lymphocyte culture tests remained normal. These data suggest that oxisuran interferes with the afferent limb of the immune system and may thereby be clinically useful in human transplantation.lld:pubmed
pubmed-article:1243205pubmed:languageenglld:pubmed
pubmed-article:1243205pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1243205pubmed:citationSubsetIMlld:pubmed
pubmed-article:1243205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1243205pubmed:statusMEDLINElld:pubmed
pubmed-article:1243205pubmed:monthNovlld:pubmed
pubmed-article:1243205pubmed:issn0041-1337lld:pubmed
pubmed-article:1243205pubmed:authorpubmed-author:PirofskyBBlld:pubmed
pubmed-article:1243205pubmed:authorpubmed-author:BardanaE...lld:pubmed
pubmed-article:1243205pubmed:authorpubmed-author:NolteM TMTlld:pubmed
pubmed-article:1243205pubmed:issnTypePrintlld:pubmed
pubmed-article:1243205pubmed:volume20lld:pubmed
pubmed-article:1243205pubmed:ownerNLMlld:pubmed
pubmed-article:1243205pubmed:authorsCompleteYlld:pubmed
pubmed-article:1243205pubmed:pagination357-61lld:pubmed
pubmed-article:1243205pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:meshHeadingpubmed-meshheading:1243205-...lld:pubmed
pubmed-article:1243205pubmed:year1975lld:pubmed
pubmed-article:1243205pubmed:articleTitleThe effect of oxisuran on human immunological responsiveness.lld:pubmed
pubmed-article:1243205pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1243205pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1243205lld:pubmed